TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed and documented recurrent ovarian, fallopian tube, or peritoneal cancer. Only patients with high-grade serous adenocarcinoma histology are eligible.~* Aged 18 years or older~* Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1~* Platinum-resistant disease (defined as progression within ≤6 months from completion of most recent platinum-containing regimen and calculated from the date of the last administered dose of platinum therapy).Subject may have been treated with additional regimen(s) subsequent to determination of platinum resistance.~* Available archived tumor tissue or if archived tissue is not available, a fresh tumor biopsy.~* Received at least 1 but not more than 4 prior therapy regimens.~Note: Maintenance therapy OR hormonal therapies should not be counted as a separate therapy.~Note: Patients who have not received prior bevacizumab must be deemed medically inappropriate OR ineligible to receive bevacizumab, refused to receive bevacizumab, or been unable to receive bevacizumab due to lack of access.~* Measurable disease according to RECIST v1.1 criteria~* Normal gastrointestinal function.~* At least 28 days between termination of prior anticancer or hormonal therapy and first administration of batiraxcept.~* Full recovery from all treatment-related toxicities to Grade 1 or less, except alopecia.~Exclusion Criteria:~* Tumors in the breast or bone~* Untreated central nervous system (CNS) metastases. Subjects requiring corticosteroid therapy for the management of their treated CNS metastases may not be on \>10 mg/day prednisone or equivalent or have demonstrated signs or symptoms of neurologic instability for 28 days or less prior to randomization.~* Primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen)~* Is being treated with concurrent anticancer therapy or other interventional treatments administered for their underlying ovarian cancer.~* Received prior therapy with PAC in the platinum-resistant recurrent setting~* Evidence of clinically significant third spacing (e.g., pleural effusions, ascites, anasarca, etc.) that requires therapeutic intervention within 28 days prior to first dose of batiraxcept/placebo

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Batiraxcept+PAC (Type: EXPERIMENTAL): Combination of batiraxcept and PAC
- Placebo+PAC (Type: PLACEBO_COMPARATOR): Placebo-controlled arm with PAC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and the willingness to sign an informed consent document~* Own a smartphone that uses Android or Apple iOS operating systems~* Participant must have one of the following:~  * Individuals with newly-diagnosed, treatment naive PDAC - all stages (applicable to Stage 1 only), or~ * Individuals with at least one of the following family phenotype and age will be included:~    * Two or more relatives with PDAC on the same side of the family, where 2 PDAC affected individuals are first-degree related (FDR) AND at least one PDAC-affected individual is an FDR of the subject; Age \>= 50 years OR 10 years before onset in family~   * Two affected FDR with PDAC; Age \>= 50 years OR 10 years before onset of an FDR~   * Any of BRCA1, BRCA2, PALB2, ATM mutations confirmed pathogenic or likely pathogenic; Age \>= 50 years OR 10 years before onset of an FDR or second-degree relative (SDR)~   * Familial atypical multiple mole-melanoma (FAMMM) with confirmed pathogenic or likely pathogenic mutation variants in: p16, CDKN2A; Age \>= 50 years~   * Known mutation carrier for STK11 (Peutz-Jeghers syndrome); Age \>= 50 years~   * Lynch syndrome (hereditary nonpolyposis colorectal cancer \[HNPCC\]) with confirmed pathogenic or likely pathogenic variants in: MLH1, MSH2, MSH6, PMS2, or EPCAM; Age \>= 50 years OR 10 years before onset of an FDR or SDR~   * Hereditary pancreatitis with confirmed PRSS1 pathogenic or likely pathogenic history of pancreatitis; Age \>= 50 years~Exclusion Criteria:~* Any medical conditions that in the opinion of the investigators would compromise participant safety and/or the integrity of the data

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Observational (HRV monitoring, questionnaire) (Type: None): Participants undergo HRV monitoring using an activity monitor (WHOOP) for a minimum of 5 days weekly for up to 1 year in patients with newly-diagnosed PDAC and up to 5 years for patients in high risk group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 2 diabetes.~* Patients in treatment with OADs (one or more) for at least 1 year who failed metabolic control (HbA1c \> 8% and \< 11%).~* FBG \> 130 mg/dl and \< 240 mg/dl.~* BMI \< 40 kg/m2 and \>25 kg/m2.~* Ability and willingness to follow a tight anti-diabetic therapy and to perform SMBG controls.~Exclusion Criteria:~* C peptide \< 0.30 nmol/l.~* Unexplained weight loss of more than 10% of body weight in the last 6 months.~* Pregnant women or women with the intention of becoming pregnant.~* Women with childbearing potential who will not use contraceptive protection.~* Breastfeeding women.~* Patients using or that have used rapid or ultra-rapid acting insulins; except for those patients that have used rapid or ultra-rapid insulins during intercurrences such as AMI, severe infection or surgery.~* Renal impairment defined as serum creatinine \>1.4 mg/dl in women and \>1.5 mg/dl in men.~* Hepatic impairment defined as GPT or GOT above 2x the normal threshold.~* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (non selective beta blockers and systemic corticosteroids).~* History of drug or alcoholic abuse.~* Diabetic retinopathy with surgical treatment in the 3 months prior to study entry or which may require surgical treatment within 6 months of study entry.~* Clinically relevant cardiovascular, gastrointestinal, hepatic, neurological, endocrine, hematological, oncologic or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, at the discretion of the investigator.~* Evidence of an uncooperative attitude, including poor compliance to any anti- diabetic treatment.~* Known hypersensitivity to insulin glargine.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
- B (Type: ACTIVE_COMPARATOR): This is the control group, following the physician's standard practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carriere Motion Appliance* Versus In-office Sectional Appliance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females~* Presenting for comprehensive orthodontic treatment at the Postgraduate orthodontic clinic at the University at Buffalo School of Dental Medicine~* Unilateral or bilateral ½-cusp to full-cusp Class II molar and canine relationship~* Growing Patients (\~12-17y 11m)~* Subjects who do not require extractions as part of treatment mechanics~* Mild to moderate crowding~Exclusion Criteria:~* Patients in mixed dentition~* Any missing teeth up to and including permanent first molars~* Bilateral molar relationship of less than ½ cusp Class II prior to appliance cementation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- In-office fabricated appliance (Type: EXPERIMENTAL): A customized in-office fabricated appliance using the printed digital model of the subject will be used for AP correction. AP correction will be completed following CMA protocol (see model description)
- Carriere Motion Appliance (Type: ACTIVE_COMPARATOR): The appropriate length appliance will be placed as directed in the CMA handbook on the maxillary first molar and canine. AP correction will be completed following CMA protocol (see model description)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male age 25-65 with documented growth hormone deficiency on stable doses x 3 months (at least) of any hormone replacement therapies and with stable MRIs x 2 years in the setting of a known pituitary mass.~Exclusion Criteria:~* Female gender~* current GH use or GH use within three months of the study~* diabetes~* hypoglycemia~* liver or kidney disease~* use of drugs that could increase GH secretion (i.e. L-dopa)~* alcohol or substance abuse~* use of investigational drugs within four weeks of our study and use of supraphysiologic doses of steroids within the previous six months.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant Human Growth Hormone first (Type: ACTIVE_COMPARATOR): Subjects will take rhGH for eight weeks followed by a two month wash out period and then will cross over to rhIGF1 for eight weeks.
- Recombinant Human IGF-1 (Type: ACTIVE_COMPARATOR): Subjects will take rhIGF1 for eight weeks followed by a two month wash out period and then will cross over to rhGH for eight weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Drugs in Lactation Analysis Consortium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years old Taking one or more drugs of interest of the study, at steady state~Exclusion Criteria:~* Being unable to communicate in English, Colostrum phase (\<1 week postpartum)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breastfeeding women on the study medications (Type: None): The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Percutaneous SCS Trial Using the DSSEP Collision Testing

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~A subject will be eligible for inclusion in this study only if all the following criteria apply:~A. Subject understands the procedures, agrees to participate in the study, and has signed and dated the informed consent form prior to the initiation of any study-related activities.~B. Subjects are male or female greater than 18 years old at the time of screening visit.~C. Pain in one or both lower extremities. D. Pain is not responding to conservative treatment such as physical therapy or medications.~E. Average pain rating of at least 4 on a scale 0 to 10, on average, prior to enrollment in the study.~F. Patient is mentally competent to make decisions.~Exclusion Criteria~A subject will not be eligible for inclusion in this study if any of the following criteria apply:~A. Female subject with childbearing potential (a premenopausal female, who is not surgically sterile).~B. Subjects who poorly cooperate or have any cognitive impairment. C. Patient with severe concomitant depression. D. Inability to communicate adequately with physician and /or study coordinator.~E. Patient is diagnosed with a psychiatric condition that will likely interfere with diagnostic accuracy of the workup protocol or with recovery following the anticipated procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DSSEP (Type: EXPERIMENTAL): DSSEP testing after SCS trial lead placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy of an Amino Acid Based Formula in Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Weight loss within the past 4 weeks~* Infants 1-12 months of age feeding a hypoallergenic formula for at least 2 weeks~* Birth weight greater than or equal to 1500 grams~* Solely enteral fed~* Infants with at least one persistent allergy symptom~* No change in medication within 10 days of beginning the study and no plans for change during the first 10 days of the study~* Signed informed consent~Exclusion Criteria:~* History of underlying condition which, in the Investigator's opinion, could interfere with normal growth, development, or assessment of the participant~* Metabolic disease requiring special attention

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 12 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Techniques to Enhance Patient Comfort in Sedation-risk Free Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Accepts adult healthy male and female patients~* At least 18 years of age~* In need of colonoscopy for screening or follow up of colonic polyps~* Willing to consent and be randomized~Exclusion Criteria:~* Patients receiving outpatient narcotic treatment~* Patients who report excessive anxiety~* Patients with moderate to severe abdominal discomfort~* Unable to provide consent~* Have poor bowel preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Warm water loading of sigmoid colon (Type: EXPERIMENTAL): Warm water loading of sigmoid colon and irrigation when spasms occur.
- Control (Type: PLACEBO_COMPARATOR): No water loading, only air and waiting for spasms to subside.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Less than 18 years of age~* Admitted for gastrostomy tube placement, with or without Nissen Fundoplication~Exclusion Criteria:~* Immunocompromised patients~* Short Bowel Syndrome (SBS)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Bolus (Type: ACTIVE_COMPARATOR): Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour.
- Continuous (Type: ACTIVE_COMPARATOR): Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electrocardiogram (ECG) Guided Peripherally Inserted Central Catheter (PICC) Placement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Require Power PICC placement as standard care~* Signed informed consent~Exclusion Criteria:~* Has an intracardiac device~* Does not have normal sinus rhythm~* Has known abnormality of central venous system~* Plasma creatinine \>=1.5 mg/dL~* Pregnancy~* Allergy or prior reaction to contrast material

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to one surgical unit (3-1) from November 1, 2007 to August 1, 2008 with a non- emergent laparoscopic colectomy.~Exclusion Criteria:~All patients with:~* History of metastatic disease~* History of inflammatory bowel disease~* Abdominal radiation treatment~* Mint allergy (the gum is mint flavored)~* Dentures~* Nasogastric tube drainage beyond the first postoperative morning~* More than one bowel anastomosis during this surgery~* Conversion to pen colectomy~* Admission to an ICI post-operatively.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: OTHER): Chewing gum or not

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: DC Vaccine in Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically-confirmed stage I and II hypermutated colorectal cancer (CRC)~* Surgically resected disease~* Male or female patients 18+ years of age~* ECOG performance status 0-1~* Certain laboratory values, performed within 14 days prior to consent~* Subjects of reproductive potential must agree to use a medically accepted birth control method during the trial and for at least two months following the trial.~* Provide written informed consent~Exclusion Criteria:~* Prior malignancy within 3 years that may put subject at risk~* Pregnant or nursing women~* Concurrent treatment with systemic immunosuppressants including corticosteroids, calcineurin inhibitors, antiproliferative agents within 2 weeks of consent. Local (inhaled or topical) steroids or replacement dose prednisone are permitted.~* Known allergy to eggs~* Any uncontrolled intercurrent illness or active ongoing infection thta may put subject at additional risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): All subjects will receive the vaccine and be followed per the schedule of procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues